open_in_newOriginal article
Tech Mahindra and NVIDIA collaborate to advance drug safety with agentic AI-powered pharmacovigilance solution

Tech Mahindra and NVIDIA collaborate to advance drug safety with agentic AI-powered pharmacovigilance solution

  • 20.03.2025 09:04
  • zawya.com
  • Keywords: Tech Mahindra and NVIDIA collaborate on AI-powered pharmacovigilance solution, AI-driven framework for drug safety management

Tech Mahindra and NVIDIA have partnered to develop an AI-powered pharmacovigilance solution using NVIDIA's AI technology. This solution automates drug safety processes, improving accuracy, speed, and efficiency while reducing manual errors and delays. It enhances case processing, compliance, and risk mitigation, transforming pharmacovigilance workflows for better patient outcomes.

Nvidia ServicesNVDAsentiment_satisfied

Estimated market influence

Tech Mahindra

Positivesentiment_satisfied
Analyst rating: N/A

Collaborated with NVIDIA to develop AI-powered pharmacovigilance solution, enhancing efficiency and accuracy in drug safety management. Their TENO framework integrates NVIDIA's AI technology, leading to reduced operational costs and improved patient outcomes.

NVIDIA

NVIDIA

Positivesentiment_satisfied
Analyst rating: Strong buy

Collaborated with Tech Mahindra to integrate their AI software into the TENO framework, improving pharmacovigigance processes. Their contribution includes providing AI Enterprise software platform which enhances human capabilities in monitoring medicine safety.

Context

Analysis of Collaboration Between Tech Mahindra and NVIDIA in Pharmacovigilance

Key Facts and Data Points

  • Collaboration Focus: Agentic AI-powered pharmacovigilance solution for drug safety management.
  • Tech Mahindra's TENO Framework: Built on NVIDIA’s AI technology, integrating NVIDIA NeMo™, NVIDIA NIM™ microservices, and NVIDIA AI Blueprints.
  • Solution Benefits:
    • Reduces turnaround times by up to 40%.
    • Enhances data accuracy by 30%.
    • Cuts operational costs by 25%.
  • Industry Impact: Manages over 1,000 daily cases of adverse drug reaction (ADR) for major drugs.

Market Implications

  • Revolutionizing Pharmacovigilance: The solution transforms pharmacovigilance from reactive to predictive, enabling proactive risk mitigation and timely case processing.
  • Regulatory Adherence: Streamlines compliance management, ensuring adherence to regulatory requirements in the pharmaceutical industry.

Competitive Dynamics

  • AI-Driven Innovation: Tech Mahindra’s integration of NVIDIA AI Enterprise software positions it as a leader in leveraging generative AI and multi-agent systems for pharmacovigilance.
  • Differentiation: The solution addresses critical challenges such as manual delays and data overload, providing a competitive edge over traditional pharmacovigilance methods.

Strategic Considerations

  • Patient Outcomes: By reducing human error and enhancing efficiency, the solution improves patient safety and outcomes.
  • Cost Efficiency: The 25% reduction in operational costs highlights the solution’s value proposition for pharma companies seeking cost-effective solutions.

Long-Term Effects

  • Industry Shift: The adoption of AI-driven pharmacovigilance is expected to accelerate, leading to a shift from manual processes to automated, intelligent systems.
  • Regulatory Impact: Enhanced safety monitoring may lead to stricter regulatory expectations and requirements for AI integration in drug safety management.

Conclusion

The collaboration between Tech Mahindra and NVIDIA represents a significant leap forward in pharmacovigilance, offering transformative benefits for the pharmaceutical industry. By leveraging agentic AI, the solution not only improves efficiency and accuracy but also sets new standards for drug safety management globally.